OCGN
Ocugen, Inc. NASDAQ Listed Dec 3, 2014$1.24
+0.81%
vs $1.23
Mkt Cap $419.8M
52w Low $0.90
18.5% of range
52w High $2.73
50d MA $1.50
200d MA $1.53
P/E (TTM)
-5.4x
EV/EBITDA
—
P/B
—
Debt/Equity
-2.7x
ROE
557.7%
P/FCF
-6.5x
RSI (14)
35.40
ATR (14)
$0.07
Beta
2.81
50d MA
$1.50
200d MA
$1.53
Avg Volume
6.6M
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
263 Great Valley Parkway · Malvern, PA 19355 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | BMO | -0.06 | -0.06 | +0.0% | 1.96 | -1.0% | -11.2% | +0.0% | -7.5% | +3.1% | +6.6% | — |
| Nov 5, 2025 | BMO | -0.06 | -0.07 | -21.7% | 1.41 | -0.7% | -2.1% | +0.0% | -1.4% | -0.7% | -1.5% | — |
| Aug 1, 2025 | BMO | -0.06 | -0.05 | +16.7% | 0.99 | +0.6% | +0.6% | +0.0% | -4.5% | +0.3% | +4.4% | — |
| May 9, 2025 | BMO | -0.06 | -0.05 | +16.7% | 0.67 | +1.9% | +4.5% | +0.0% | +0.4% | -1.1% | +2.1% | — |
| Mar 5, 2025 | BMO | -0.05 | -0.05 | +0.0% | 0.57 | +1.2% | +10.0% | +0.0% | -3.2% | -8.8% | -1.8% | — |
| Nov 14, 2024 | BMO | -0.05 | -0.05 | +0.0% | 1.00 | +2.0% | -6.1% | +0.0% | -2.9% | -4.1% | +5.1% | — |
| Aug 8, 2024 | BMO | -0.06 | -0.04 | +33.3% | 1.28 | -0.8% | -2.3% | +0.0% | +4.0% | +1.5% | -3.0% | — |
| Apr 16, 2024 | BMO | -0.06 | -0.04 | +33.3% | 1.59 | +0.6% | -9.4% | +0.0% | -8.3% | +0.0% | -6.1% | — |
| Mar 26, 2024 | BMO | -0.06 | -0.03 | +50.0% | 1.73 | +0.0% | +2.9% | +0.0% | -7.9% | -6.1% | -10.4% | — |
| Nov 9, 2023 | BMO | -0.08 | -0.06 | +25.0% | 0.37 | +0.0% | -2.3% | +0.0% | +1.4% | +2.5% | +1.5% | — |
| Aug 21, 2023 | BMO | -0.08 | -0.10 | -25.0% | 0.44 | -2.5% | -9.0% | +0.0% | +16.9% | -0.8% | -2.1% | — |
| May 5, 2023 | BMO | -0.11 | -0.07 | +36.4% | 0.70 | +1.4% | +2.6% | +0.0% | +1.4% | +2.5% | -6.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $1.92 | $1.98 | +3.1% | +1.6% | +0.5% | -4.6% | -6.4% | +3.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.92 | $1.98 | +3.1% | +1.6% | +0.5% | -4.6% | -6.4% | +3.4% |
| Mar 5 | Chardan Capital | Maintains | Buy → Buy | — | $1.96 | $1.94 | -1.0% | -11.2% | -7.5% | +3.1% | +6.6% | +29.9% |
| Jan 20 | Chardan Capital | Maintains | Buy → Buy | — | $1.69 | $1.71 | +1.2% | -1.2% | -10.8% | +10.7% | +0.6% | -4.2% |
| Sep 19 | Chardan Capital | Maintains | Buy → Buy | — | $1.40 | $1.34 | -4.3% | -4.3% | +3.7% | +19.4% | -1.2% | -7.3% |
| Aug 4 | Chardan Capital | Maintains | Buy → Buy | — | $0.99 | $1.00 | +0.6% | +0.6% | -4.5% | +0.3% | +4.4% | -0.2% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.98 | $1.07 | +9.1% | +5.0% | +1.0% | -1.0% | -4.5% | -1.4% |
| Jun 24 | Chardan Capital | Maintains | Buy → Buy | — | $0.98 | $1.07 | +9.1% | +5.0% | +1.0% | -1.0% | -4.5% | -1.4% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.67 | $0.68 | +1.9% | +4.5% | +0.4% | -1.1% | +2.1% | +6.9% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $0.67 | $0.68 | +1.9% | +4.5% | +0.4% | -1.1% | +2.1% | +6.9% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.57 | $0.58 | +1.2% | +10.0% | -3.2% | -8.8% | -1.8% | +5.5% |
| Mar 6 | Chardan Capital | Maintains | Buy → Buy | — | $0.57 | $0.58 | +1.2% | +10.0% | -3.2% | -8.8% | -1.8% | +5.5% |
| Feb 13 | Chardan Capital | Maintains | Buy → Buy | — | $0.66 | $0.68 | +3.0% | +6.5% | +2.2% | +1.5% | -4.6% | +0.6% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.66 | $0.68 | +3.0% | +6.5% | +2.2% | +1.5% | -4.6% | +0.6% |
| Jan 23 | Chardan Capital | Maintains | Buy → Buy | — | $0.76 | $0.75 | -0.8% | +3.1% | +0.0% | -6.3% | -2.6% | +3.9% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.79 | $0.80 | +1.7% | -4.5% | -2.4% | -0.6% | -1.9% | -0.7% |
| Nov 18 | Chardan Capital | Maintains | Buy → Buy | — | $0.94 | $0.94 | +0.1% | -2.9% | -4.1% | +5.1% | -1.9% | +0.7% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.96 | $0.97 | +1.4% | +4.4% | -6.1% | -2.9% | -4.1% | +5.1% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.99 | $1.00 | +1.4% | +8.5% | -4.7% | -6.1% | +4.4% | -6.1% |
| Nov 8 | Chardan Capital | Maintains | Buy → Buy | — | $1.08 | $1.09 | +0.9% | -8.7% | +8.5% | -4.7% | -6.1% | +4.4% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.93 | $0.93 | +0.0% | -2.1% | -1.8% | +3.5% | +9.2% | -4.6% |
| May 15 | Chardan Capital | Maintains | Buy → Buy | — | $1.70 | $1.74 | +2.4% | +15.3% | +1.0% | -3.5% | +0.5% | -3.6% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.70 | $1.74 | +2.4% | +15.3% | +1.0% | -3.5% | +0.5% | -3.6% |
| Apr 22 | Chardan Capital | Maintains | Buy → Buy | — | $1.32 | $1.35 | +2.3% | -6.1% | +0.8% | -5.6% | +0.0% | +8.5% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.38 | $1.37 | -0.7% | +9.4% | +0.0% | +21.2% | +2.7% | -9.0% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.04 | -1.9% | -6.0% | -20.3% | +13.3% | +10.0% | -4.9% |
| Jan 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.53 | $0.56 | +4.9% | +2.4% | +5.3% | -5.9% | +4.7% | -2.8% |
| Aug 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.45 | $0.45 | +0.0% | -4.6% | -0.2% | +5.1% | -4.9% | +0.0% |
| Aug 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.40 | $0.42 | +4.2% | +16.9% | -0.8% | -2.1% | -1.1% | +1.8% |
| May 8 | Chardan Capital | Maintains | Buy → Buy | — | $0.70 | $0.71 | +1.4% | +2.6% | +1.4% | +2.5% | -6.2% | -3.4% |
| Apr 14 | Chardan Capital | Maintains | Buy → Buy | — | $0.85 | $0.87 | +2.0% | -6.0% | +2.5% | +6.7% | -0.3% | -5.7% |
| Mar 1 | Mizuho | Maintains | Buy → Buy | — | $1.00 | $1.01 | +1.4% | +0.2% | +0.2% | +4.0% | -5.5% | -1.8% |
| Mar 1 | Chardan Capital | Upgrade | Neutral → Buy | — | $1.00 | $1.01 | +1.4% | +0.2% | +0.2% | +4.0% | -5.5% | -1.8% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.84 | $2.80 | -1.4% | +1.4% | -3.8% | -3.6% | -4.1% | -4.3% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.83 | $1.80 | -1.6% | +4.4% | +9.9% | -4.3% | +10.4% | -7.2% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.22 | $3.14 | -2.5% | +9.3% | +1.4% | -1.7% | -6.3% | -23.1% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.69 | $6.89 | +3.0% | -5.2% | -3.3% | +2.1% | +4.0% | +0.5% |
| Jun 11 | Roth Capital | Downgrade | Buy → Neutral | — | $6.69 | $6.89 | +3.0% | -5.2% | -3.3% | +2.1% | +4.0% | +0.5% |
| May 7 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $9.58 | $8.04 | -16.1% | -4.1% | +10.7% | -2.7% | -13.0% | -4.4% |
| Mar 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.60 | $12.03 | +25.3% | +9.0% | -14.2% | -2.6% | -1.3% | +1.7% |
| Feb 9 | Chardan Capital | Downgrade | Buy → Neutral | — | $15.81 | $12.94 | -18.2% | -20.2% | -18.7% | +7.2% | -6.5% | +6.6% |
| Feb 4 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.81 | $3.26 | +16.0% | +15.7% | +61.5% | +201.1% | -20.2% | -18.7% |
| Jun 3 | Chardan Capital | Maintains | Buy → Buy | — | $0.22 | $0.23 | +1.8% | +0.9% | +0.9% | +11.1% | +13.6% | +5.3% |
| Jun 1 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $0.31 | $0.25 | -19.4% | -25.8% | -3.9% | +0.9% | +0.9% | +11.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Johnson-Greene Treerita EssalimaOff | Chief Financial Officer | Buy | 21,000 | $1.23 | $26K | 521,000 | +0.81% | — |
8-K · 5.02
!!! Very High
Ocugen, Inc. -- 8-K 5.02: Executive Change
May 14
8-K · 2.02
!! High
Ocugen, Inc. -- 8-K 2.02: Earnings Results
Ocugen reported Q1 2026 financial results on May 5, 2026, providing investors with operational performance metrics for the quarter ended March 31, 2026.
May 5
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Ocugen disclosed forward-looking statements, likely regarding clinical trials or commercialization plans, signaling potential near-term catalysts but increased execution risk that investors should monitor closely.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Ocugen disclosed forward-looking statements via press release and presentations, signaling upcoming announcements about clinical or commercial developments that investors should monitor for material catalysts affecting the biotech stock's trajectory.
Mar 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
This boilerplate risk disclosure suggests Ocugen faces significant operational uncertainties that could negatively impact results; investors should review detailed SEC filings before trading.
Mar 20
8-K · 8.01
!! High
Ocugen, Inc. -- 8-K 8.01: Material Event / Announcement
Ocugen won expedited hearing approval for its shareholder vote petition, allowing the company to declare stockholder approval of its Share Increase Proposal from the 2024 Annual Meeting.
Mar 4
8-K
Ocugen, Inc. -- 8-K Filing
Ocugen released Q4 and full-year 2025 financial results on March 4, 2026, with a conference call scheduled for 8:30 a.m. to discuss business performance and updates.
Mar 4
8-K · 5.02
!!! Very High
Ocugen, Inc. -- 8-K 5.02: Executive Change
Ocugen appoints Ms. Johnson-Greene as principal financial officer while she resigns from the board, signaling potential leadership restructuring that investors should monitor for strategic implications.
Feb 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 13,804,111 | $25M | New | Mar 2026 |
| 2 | Millennium Management | 13,727,192 | $25M | Added | Mar 2026 |
| 3 | Marshall Wace, Llp | 8,052,350 | $15M | Added | Mar 2026 |
| 4 | Ubs Group Ag | 7,280,320 | $13M | Added | Mar 2026 |
| 5 | Rtw Investments, Lp | 6,666,666 | $12M | New | Mar 2026 |
| 6 | Qube Research & Technologies Ltd | 3,773,066 | $7M | New | Mar 2026 |
| 7 | Citadel Advisors Llc | 2,809,157 | $5M | Added | Mar 2026 |
| 8 | Two Sigma Investments, Lp | 2,251,282 | $4M | Added | Mar 2026 |
| 9 | Jane Street Group, Llc | 1,692,134 | $2M | Added | Dec 2025 |
| 10 | Bank Of America Corp /de/ | 1,174,180 | $2M | Added | Mar 2026 |
| 11 | Vanguard Portfolio Management Llc | 935,799 | $2M | New | Mar 2026 |
| 12 | Point72 Asset Management | 834,490 | $2M | Added | Mar 2026 |
| 13 | Susquehanna International Group, Llp | 769,549 | $1M | Reduced | Mar 2026 |
| 14 | Rinkey Investments | 991,186 | $1M | Reduced | Dec 2025 |
| 15 | Northern Trust Corp | 713,736 | $1M | Added | Mar 2026 |
| 16 | Morgan Stanley | 926,908 | $1M | Added | Dec 2025 |
| 17 | Hrt Financial Lp | 376,594 | $681K | New | Mar 2026 |
| 18 | Barclays Plc | 230,618 | $417K | Added | Mar 2026 |
| 19 | Mitsubishi Ufj Asset Management Co., Ltd. | 204,168 | $370K | Reduced | Mar 2026 |
| 20 | Catalyst Funds Management Pty Ltd | 180,600 | $327K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 15
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | State Street(R) SPDR(R) S&P(R) Biotech ETF | 5,222,819 | $9M | Mar 2026 |
| 2 | State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 2,554,326 | $5M | Mar 2026 |
| 3 | Fidelity Extended Market Index Fund | 1,639,988 | $3M | Feb 2026 |
| 4 | iShares Core S&P Total U.S. Stock Market ETF | 645,821 | $1M | Mar 2026 |
| 5 | Fidelity Total Market Index Fund | 582,856 | $1M | Feb 2026 |
| 6 | Fidelity Series Total Market Index Fund | 449,915 | $819K | Feb 2026 |
| 7 | iShares Genomics Immunology and Healthcare ETF | 477,437 | $692K | Jan 2026 |
| 8 | Fidelity Nasdaq Composite Index Fund | 183,068 | $333K | Feb 2026 |
| 9 | Schwab Total Stock Market Index Fund | 170,254 | $247K | Jan 2026 |
| 10 | Fidelity ZERO Total Market Index Fund | 159,007 | $231K | Jan 2026 |
| 11 | Fidelity ZERO Extended Market Index Fund | 97,369 | $141K | Jan 2026 |
| 12 | Victory Extended Market Index Fund | 34,715 | $50K | Jan 2026 |
| 13 | State Street Balanced Index Fund | 3,448 | $6K | Mar 2026 |
| 14 | Guggenheim Active Allocation Fund | 2,201 | $4K | Feb 2026 |
| 15 | BlackRock Small Cap Index V.I. Fund | — | — | Mar 2026 |
Valuation
Market Cap
$419.8M
Enterprise Value
$381.2M
P/E (TTM)
-5.39x
Forward P/E
—
PEG Ratio
-0.40x
P/B
—
P/S
84.34x
P/FCF
-6.51x
EV/EBITDA
—
Shares Out
300.2M
Financials (TTM)
Revenue
$4.4M
Net Income
-$67.8M
EBITDA
-$60.5M
Free Cash Flow
-$57.1M
Op Cash Flow
-$57.0M
EPS Basic
$-0.23
EPS Diluted
$-0.23
EPS Forward
$-0.22
Gross Margin
45.9%
Op Margin
-1425.7%
Net Margin
-1537.4%
Balance Sheet
Total Assets
$43.5M
Total Liab.
$56.5M
Total Equity
-$12.2M
Cash
$18.6M
LT Debt
$27.5M
Book Value/Sh
$-0.04
Debt/Equity
-2.72x
Current Ratio
1.06
Quick Ratio
1.06
Returns & Growth
ROE
557.7%
ROA
-155.9%
ROIC
-278.6%
Rev Growth YoY
+8.8%
EPS Growth YoY
-15.0%
Price Returns
2W
-5.5%
1M
-20.2%
3M
-24.2%
6M
+11.3%
12M
+65.1%
Technicals
52W High
$2.73
52W Low
$0.90
50d MA
$1.50
200d MA
$1.53
RSI (14)
35.40
ATR (14)
$0.07
Beta
2.81
Avg Volume
6.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.00
High
$6.00
Low
$3.50
Median
$5.00
Data updated apr 26, 2026 4:52pm
· Source: financialmodelingprep.com